Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities (Q59210186)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Molecular diagnostics and personalized medicine in oncology: challenges and opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

main subject

diagnosis

0 references

personalized medicine

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Anna Maria Rachiglio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Cristin Roma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Francesca Fenizia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Raffaella Pasquale

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Michele Santangelo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Francesca Bergantino

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Susan Costantini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Antonella De Luca

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ana Cláudia C. Espósito

5

object named as

Claudia Esposito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

8

Alessia Iannaccone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Maria Libera La Porta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Filippo Micheli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cellular Biochemistry

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

514-524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

ROS1 rearrangements define a unique molecular class of lung cancers

13 February 2020

cites work

1 reference

Triple negative breast cancer: from molecular portrait to therapeutic intervention.

21 January 2018

1 reference

Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.

21 January 2018

1 reference

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time

21 January 2018

1 reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

21 January 2018

1 reference

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

Clinical implications of the cancer genome

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

Sequencing technologies - the next generation

21 January 2018

1 reference

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

Target-based therapies in breast cancer: current status and future perspectives.

21 January 2018

1 reference

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment

21 January 2018

1 reference

BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair

21 January 2018

1 reference

Chipping away at the lung cancer genome.

21 January 2018

1 reference

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

BRAF targeted therapy changes the treatment paradigm in melanoma

21 January 2018

1 reference

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development

21 January 2018

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

The current state of targeted therapy in melanoma: this time it's personal

21 January 2018

1 reference

Gene-expression signatures in breast cancer

21 January 2018

1 reference

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

Molecular genetics of lung cancer in people who have never smoked

21 January 2018

1 reference

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

Cancer genomics: technology, discovery, and translation

21 January 2018

1 reference

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

21 January 2018

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE11156

Identifiers

DOI

10.1002/JCB.24401

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22991232%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference